Article Text

PDF
150
MS FINE STUDY: GILENYA REAL WORLD EXPERIENCE IN THE UK
  1. Gordon Mazibrada1,
  2. Paula Pamies Garcia-Ganuza2
  1. 1 University Hospital Birmingham NHS Foundation Trust
  2. 2 Novartis Pharmaceuticals

Abstract

Background Fingolimod (Gilenya) is a sphingosine 1-phosphate receptor modulator. Fingolimod was first granted a European license in multiple sclerosis in 2011 and first approved for use in the UK by the National Institute for Health and Care Excellence (NICE) in 2012 for patients with highly active relapsing remitting multiple sclerosis (RRMS).

MSFine is an observational, retrospective study with the aim to evaluate patient characteristics and clinical outcomes at 12 months post-treatment in patients receiving Gilenya for RRMS in UK clinical practice.

Objective To report primary and secondary efficacy outcomes of all patients included in MS Fine study.

Methodology Retrospective review of patient notes. 11 centers recruited 209 patients.

Results Analysis, including baseline characteristics, is reported for 209 patients. Results: After 1 year of treatment with Gilenya, 83.5% were free of relapses (n=209); 91.3% free of disability progression (n=23); 81% of patients free of clinical disease activity (n=22); 66.6% were free of radiological disease activity (n=93). No new safety signals reported.

Conclusion Fingolimod is shown to be an effective therapy in patients with highly active RRMS in real world clinical practice in the UK.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.